Multiple myeloma

Majority of patients with advanced multiple myeloma respond to CAR T-cell therapy targeting an anti-B-cell maturation antigen in a phase I trial

May 2, 2019

A phase I clinical trial of 33 patients infused with a CAR T-cell therapy using T cells genetically engineered to express an anti-B-cell maturation antigen (BCMA) CAR showed that 85 percent of patients had the burden of their advanced multiple myeloma cut by half or more.  Read more...

CT scan of a patient with mesothelioma

Heritable mutations may indicate responsiveness to platinum chemotherapy in malignant mesothelioma

May 1, 2019

In a genetic analysis of 434 patients with malignant mesothelioma who had undergone platinum chemotherapy, those who carried heritable mutations in BAP1and other DNA repair genes had significantly longer overall survival than those without these mutations. The findings hint at personalized approaches to the disease.   Read more...

Three-dimensional structure of HIV infected and uninfected T cells interacting

Envelope glycoprotein mutations allow HIV-1 to escape antiretroviral therapy in a lab-based study

Apr 12, 2019

CCR investigators have discovered that HIV-1 can compensate for a variety of mutations that block its replication by acquiring mutations in the envelope glycoprotein. Because antiretroviral therapies work by inhibiting viral replication, these findings may have implications for HIV-1 drug resistance. Read more...

Travis, an NF1 patient

MEK inhibitor selumetinib granted breakthrough designation by FDA to treat neurofibromatosis type 1 in pediatric patients

Apr 12, 2019

The U.S. Food and Drug Administration last week granted breakthrough therapy designation for the MEK 1/2 inhibitor selumetinib. The designation is for the treatment of pediatric patients aged three years and older with neurofibromatosis type 1 (NF1) symptomatic and/or progressive, inoperable plexiform neurofibromas (PN), a rare, incurable genetic condition. Read more...

Artistic rendering of a T cell immersed in the tumor microenvironment exposed to high levels of potassium

Harnessing T-cell “stemness” could enhance cancer immunotherapy

Mar 28, 2019

A new study led by Nicholas Restifo, M.D., Senior Investigator in CCR’s Surgery Branch, sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Sciencesuggest a way to enhance the effectiveness of immunotherapies for cancer treatment.  Read more...

Samples from acute myeloid leukemia patients with the splicing factor mutation

CCR researchers discover how protein translation disruptions can lead to cancer

Mar 11, 2019

A mutation in the gene U2AF1, which codes for a protein involved in cutting out key pieces of RNA, can also have widespread effects on the translation of messenger RNA into proteins. A close look at one affected protein, interleukin 8 (IL8), revealed increased production as a result of the mutation, leading to inflammation and cancer spread.  Read more...

metastatic melanoma cells

Drug found effective in mice for uveal melanoma

Mar 6, 2019

Drugs that directly target the transcription factor YAP, which is associated with the growth of uveal melanoma, are too toxic to be used in patients. A new study in mice, however, finds a new, safe and effective way for targeting the YAP pathway. Read more...


Deep-imaging study reveals extensive variability in 3D configuration of genomes between cells

Feb 21, 2019

A new study analyzing chromatin in single cells using advanced imaging methods, led by CCR Director Tom Misteli, Ph.D., has revealed more heterogeneity in the 3D configuration of genomes than previously thought. Read more...

Nanoparticles in brain metastases

New strategy for treating brain tumors with mutations in metabolic enzymes

Feb 20, 2019

Cancers with mutations in key metabolic enzymes disrupt oxygen metabolism and cause a buildup of reactive oxygen species in mice. This mutation is found in about 80 percent of grade II/III gliomas, or brain tumors, in humans. By inhibiting the action of a protein that allows cancer cells to survive, investigators have potentially found a new strategy for treating cancers with these mutations. Read more...

A scanning electron micrograph of a T lymphocyte

Researchers identify a key molecule that enhances T cell-based immunotherapy

Feb 19, 2019

The transcription factor c-Myb plays a critical role in regulating T cell stemness. Researchers showed that increasing expression of this transcription factor in T cells launches a powerful, long-lasting antitumor response in mice.  Read more...